Compare TRVI & PHIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRVI | PHIN |
|---|---|---|
| Founded | 2011 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | 2019 | 2023 |
| Metric | TRVI | PHIN |
|---|---|---|
| Price | $13.31 | $73.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $28.18 | ★ $84.40 |
| AVG Volume (30 Days) | ★ 1.5M | 349.8K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.64% |
| EPS Growth | 31.91 | ★ 84.09 |
| EPS | N/A | ★ 3.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.85 |
| Revenue Next Year | N/A | $3.11 |
| P/E Ratio | ★ N/A | $19.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $51.38 |
| 52 Week High | $20.22 | $86.94 |
| Indicator | TRVI | PHIN |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 68.57 |
| Support Level | $13.00 | $69.02 |
| Resistance Level | $13.55 | $74.43 |
| Average True Range (ATR) | 0.88 | 2.80 |
| MACD | 0.06 | 0.91 |
| Stochastic Oscillator | 20.92 | 96.88 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.